Evidence map›Paper›PMID 40896696›Full record

ReviewIranian journal of basic medical sciences2025

CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.

Bahjat Alhasso, Abdulkareem Shareef, Lalji Baldaniya, Rami Oweis, Renuka Jyothi, Udaybir Singh, Samir Sahoo, Ashish Singh Chauhan, Hayder Naji Sameer, Ahmed Yaseen and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Smart micro/nanoneedles for gene delivery.Iranian journal of basic medical sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bahjat AlhassoCollege of Pharmacy, Alnoor University, Nineveh, Iraq.
Abdulkareem ShareefAhl al bayt University, Karbala, Iraq.
Lalji BaldaniyaMarwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat, India.
Rami OweisDepartment of Pharmacy, Modern College of Business and Science, Muscat, Oman.
Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Udaybir SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Samir SahooDepartment of General Medicine, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha-751003, India.
Ashish Singh ChauhanUttaranchal Institute of Pharmaceutical Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Hayder Naji SameerCollage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Ahmed YaseenGilgamesh Ahliya University, Baghdad, Iraq.
Zainab H AthabDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Mohaned AdilPharmacy college, Al-Farahidi University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a significant global health challenge, necessitating advanced molecular therapies to improve outcomes. The CRISPR/Cas9 genome-editing platform has emerged as a transformative tool in CRC research, enabling precise genomic modifications to suppress tumor progression, enhance chemosensitivity, and modulate oncogenic pathways. This review highlights CRISPR/Cas9 applications in CRC models, including MC38 murine and CaCO-2 cell lines, where targeted gene edits demonstrate tumor-suppressive effects. For instance, Par3L protein knockout via CRISPR/Cas9 inhibits proliferation, induces apoptosis, and sensitizes cells to chemotherapy by regulating AMPK signaling. Additionally, AAV-mediated CRISPR editing shows promise in HPV16-driven CRC models. Despite its potential, clinical translation faces challenges such as off-target effects, immunogenicity, and delivery limitations. Advances in engineered CRISPR variants (e.g., xCas9, HypaCas9) and innovative delivery systems are refining specificity and efficacy. CRISPR/Cas9 also accelerates biomarker discovery, paving the way for precision oncology. Overcoming current barriers could revolutionize CRC therapeutics, offering personalized treatment paradigms.

Indexed as

Colorectal Cancer (CRC) Gene TherapyCRISPR/Cas9Genome EditingOncogenic PathwaysTumor Suppression

Identifiers

PMID40896696
PMCPMC12399063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.